Figure 6.

MGN1703 treatment induce detectable plasma viremia. A, Analyses of plasma human immunodeficiency virus type 1 (HIV-1) RNA revealed that 6 of 15 participants had quantifiable plasma HIV-1 RNA (range, 21–1571 copies/mL) during MGN1703 treatment. Gray area represents the 4-week dosing period. B, Cell-associated unspliced (CA-US) HIV-1 RNA from 1 × 10⁶ CD4⁺ T cells. Time-points depicted in the graph are as follows: “baseline”: average of day –30 and day 0 data (prior to dosing); day 4 (24 hours after second dose); day 5 (48 hours after second dose); day 10 (48 hours after third dose); day 24 (24 hours after eighth/last dose); follow-up: average of follow-up visit data on day 37 and 79 (14 and 42 days after last dose). No measurable induction of HIV-1 transcription was observed in peripheral blood during MGN1703 treatment; however, a significant reduction was observed at follow-up (n = 13). C, Total HIV-1 DNA (n = 14) was analyzed with digital droplet polymerase chain reaction from 5 × 10⁶ CD4⁺ T cells on baseline and follow-up (14 days after last dose). Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05.